Press releases
Browse US-specific press releases here.
Please visit our Global website for access to global press releases dating back to 2009.
-
GSK and Queer Eye's Thom Filicia Partner on Blood Cancer Awareness Initiative
GSK has partnered with former Queer Eye star Thom Filicia to launch Mapping Myelofibrosis, a new health education initiative.
Download (PDF, 155.2KB) -
GSK Celebrates 2023 IMPACT Award Winners
GSK is honoring 20 nonprofits for their contributions to improving health in the Triangle (North Carolina) and Greater Philadelphia regions.
Download (PDF, 160.3KB) -
New data for AREXVY, GSK’s RSV vaccine, show potential to help protect adults aged 50 to 59 at increased risk for RSV disease
GSK today announced positive preliminary results from its phase III trial
Download (PDF, 202.4KB) -
Ojjaara (momelotinib) approved in the US as the first and only treatment indicated for myelofibrosis patients with anemia
Ojjaara is a once-a-day, oral JAK1/JAK2 and activin A receptor type 1 (ACVR1) inhibitor.
Download (PDF, 252.8KB) -
GSK and Earvin “Magic” Johnson to Host Community Awareness Events about Older Adult Risk for RSV at YMCA Locations
GSK and YMCA of the USA will host GSK’s Sideline RSV “Community Conversations” event series to raise awareness about RSV infection.
Download (PDF, 195.3KB) -
GSK announces AREXVY, its respiratory syncytial virus (RSV) vaccine, is now available at all major US retail pharmacies
AREXVY is now widely available in major retail pharmacies and anticipated to be covered by most Medicare and commercial insurance plans.
Download (PDF, 193.9KB) -
Jemperli (dostarlimab-gxly) plus chemotherapy approved in the US as the first new frontline treatment option in decades for dMMR/MSI-H primary advanced or recurrent endometrial cancer
Jemperli is the only immuno-oncology treatment approved in a frontline setting for this patient population in combination with chemotherapy
-
GSK is first to ship influenza vaccine doses for the 2023-24 flu season in US
GSK supports annual flu immunization with its shipping of FLULAVAL QUADRIVALENT and FLUARIX QUADRIVALENT
-
GSK receives US FDA Fast Track designation for investigational vaccine against gonorrhoea
Fast Track designation accelerates the vaccine candidate’s path to US FDA submission for the prevention of Neisseria gonorrhoeae infection
-
US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices votes to recommend AREXVY for the prevention of RSV disease in adults aged 60 and older with shared clinical decision making
Committee recommendations mean over 55 million older adults in the US could have access to RSV vaccination for the first time
-
GSK shares positive data for AREXVY, its respiratory syncytial virus (RSV) older adult vaccine, indicating protection over two RSV seasons
GSK shares positive data for AREXVY, its respiratory syncytial virus older adult vaccine, indicating protection over two RSV seasons
-
GSK and Lifetime® Release Short Film Featuring Soleil Moon Frye and Melissa Joan Hart Urging Parents to “Ask2BSure” about Meningitis B
The film, “I Never Thought to Ask: A Mom's Quest for Answers” includes important questions parents can ask their teen’s doctor.
-
GSK receives US FDA file acceptance for Jemperli (dostarlimab-gxly) plus chemotherapy for the treatment of dMMR/MSI-H primary advanced or recurrent endometrial cancer
Submission accepted for Priority Review.
-
GSK announces the COiMMUNITY Initiative to help achieve higher adult vaccination rates in the US
The COiMMUNITY Initiative is designed to help reduce health inequities and set a new precedent for adult immunization rates in the US.
-
US FDA approves GSK’s AREXVY, the world’s first respiratory syncytial virus (RSV) vaccine for older adults
Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time.
-
GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health
Acquisition further strengthens specialty medicines and respiratory pipeline.
-
Phase III RUBY clinical trial demonstrates potential of Jemperli (dostarlimab-gxly) plus chemotherapy to redefine the treatment of primary advanced or recurrent endometrial cancer versus chemotherapy alone
Interim results from Part 1 of the RUBY clinical trial in primary advanced or recurrent endometrial cancer.
-
GSK and Earvin “Magic” Johnson Partner to Raise Awareness of Risk of RSV in Older Adults
GSK launches national health education campaign, Sideline RSV, to highlight risk of Respiratory Syncytial Virus (RSV).
-
US FDA Advisory Committee votes to support effectiveness and safety of GSK’s respiratory syncytial virus older adult vaccine candidate
Committee votes unanimously that the data support the effectiveness of the vaccine and 10-2 that the data support the safety of the vaccine
-
Landmark New England Journal of Medicine publication reinforces potential of GSK’s respiratory syncytial virus older adult vaccine candidate
First peer-reviewed publication of phase III RSV vaccine data in older adults, including those with comorbidities who are most at risk.
